DrugPatentWatch Database Preview
Vertex Pharms Inc Company Profile
What is the competitive landscape for VERTEX PHARMS INC, and what generic alternatives to VERTEX PHARMS INC drugs are available?
VERTEX PHARMS INC has four approved drugs.
There are thirty-three US patents protecting VERTEX PHARMS INC drugs.
There are four hundred and five patent family members on VERTEX PHARMS INC drugs in thirty-eight countries and thirty-one supplementary protection certificates in fourteen countries.
Summary for Vertex Pharms Inc
| International Patents: | 405 |
| US Patents: | 33 |
| Tradenames: | 3 |
| Ingredients: | 3 |
| NDAs: | 4 |
Drugs and US Patents for Vertex Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-003 | Apr 29, 2019 | RX | Yes | No | Start Trial | Start Trial | |||||
| Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-003 | Apr 29, 2019 | RX | Yes | No | Start Trial | Start Trial | |||||
| Vertex Pharms Inc | ORKAMBI | ivacaftor; lumacaftor | TABLET;ORAL | 206038-001 | Jul 2, 2015 | RX | Yes | Yes | 7,973,038 | Start Trial | Start Trial | ||||
| Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-002 | Mar 17, 2015 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Vertex Pharms Inc | ORKAMBI | ivacaftor; lumacaftor | GRANULE;ORAL | 211358-002 | Aug 7, 2018 | RX | Yes | Yes | 8,410,274 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Vertex Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Hong Kong | 1105970 | Start Trial |
| Slovenia | 2404919 | Start Trial |
| Australia | 2010251789 | Start Trial |
| South Korea | 20140009566 | Start Trial |
| Hong Kong | 1203840 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Vertex Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2404919 | 122016000035 | Germany | Start Trial | PRODUCT NAME: 3-(6-((1-(2,2-DIFLUOR-1,3-BENZODIOXOL-5-YL)CYCLOPROPANCARBONYL)AMINO)-3-METHYLPYRIDIN-2-YL)BENZOESAEURE, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, ODER EIN ESTER-PRODRUG DAVON.; REGISTRATION NO/DATE: EU/1/15/1059 20151119 |
| 1773816 | 2015/036 | Ireland | Start Trial | PRODUCT NAME: N-(5-HYDROXYL-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3- CARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/12/782/001-002 20120723 |
| 1773816 | 35/2015 | Austria | Start Trial | PRODUCT NAME: N-(5-HYDROXY-2,4DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLIN-3-CARBOXAMID ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/782/001, EU/1/12/782/002 (MITTEILUNG) 20120725 |
| 2225230 | 2017009 | Norway | Start Trial | PRODUCT NAME: 3-6-(1-(2,2-DIFLUOR-1,3-; REG. NO/DATE: EU/1/15/1059 20151210 |
| 2404919 | 2016/018 | Ireland | Start Trial | PRODUCT NAME: 3-(6-((1-(2,2-DIFLUORO-1,3-BENZODIOXOL-5- YL)CYCLOPROPANECARBONYL)AMINO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID (LUMACAFTOR), OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR AN ESTER PRODRUG THEREOF; REGISTRATION NO/DATE: EU/1/15/1059 20151119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
